Market Pulse Archives

Nov. 30, 2021, 8:26 a.m. EST

First Wave BioPharma stock rockets after upbeat news on treatment for COVID-19-related GI infections

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    First Wave BioPharma Inc. (FWBI)
  • X
    iShares Biotechnology ETF (IBB)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Shares of First Wave BioPharma Inc. /zigman2/quotes/207562037/composite FWBI +3.03% rocketed 46.6% on very heavy volume in premarket trading Tuesday, after the biopharmaceutical company said an independent data monitoring committee (DMC) recommended continued enrollment in a Phase 2 trial of its treatment (FW-COV) for COVID-19-related gastrointestinal (GI) infections. Trading volume spiked to 12.0 million shares ahead of the open, enough to make the stock the most actively traded in the premarket, and compared with the full-day average of about 1.4 million shares. FW-COV is an oral tablet developed to remove SARS-CoV-2 from the GI tract. The DMC recommendation was based on its review of safety data, as no safety issues were uncovered. "Because niclosamide targets the entire virus, and not just the spike protein, we believe that FW-COV may prove effective against multiple strains of COVID-19 and may provide an effective therapeutic to help millions of COVID-19 patients overcome the debilitating and often overlooked effect the virus can have on the GI system," said Chief Executive James Sapirstein. The stock, which underwent a 1-for-10 reverse stock split in September, and closed at a split-adjusted record low of $1.86 on Nov. 23, has plunged 68.5% over the past three months through Monday, while the iShares Biotechnology ETF /zigman2/quotes/206189322/composite IBB +1.56% has lost 9.3% and the S&P 500 /zigman2/quotes/210599714/realtime SPX +1.22% has gained 2.8%.

/zigman2/quotes/207562037/composite
US : U.S.: Nasdaq
$ 1.36
+0.04 +3.03%
Volume: 51,070
Jan. 20, 2022 12:07p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$16.45 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/206189322/composite
US : U.S.: Nasdaq
$ 133.88
+2.05 +1.56%
Volume: 1.04M
Jan. 20, 2022 12:06p
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,588.16
+55.40 +1.22%
Volume: 970.75M
Jan. 20, 2022 12:07p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.